

WHAT IS OTOTOXICITY?



The 5-year survival rate for childhood cancers due to major treatment advances is now 85% or higher.¹ Cisplatin-based therapy is an indispensable component of treatment for pediatric solid-tumor cancers; however, an unfortunate side effect of cisplatin-based chemotherapy is irreversible ototoxicity (or hearing loss). Ototoxicity is caused by irreversible damage to hair cells in the cochlea. This damage is generally dose-dependent, bilateral (affecting both ears), and can be progressive.^{2,3,4}


From the very first treatment cycle, pediatric patients can suffer cisplatin-induced ototoxicity that may progressively worsen even after treatment ends.⁵

WHO DOES IT AFFECT?

Approximately **5,000 children** (≤ 18 years) are diagnosed with a solid tumor and eligible for treatment with a platinum-based chemotherapy every year in the United States, and a similar number in Europe.

Approximately **70% of these patients** (~3,500 in the US) are diagnosed with non-metastatic, localized disease.⁶

Annual incidence of pediatric solid tumor cases eligible for platinum-based therapy in both U.S. and EU markets



Hearing loss can be seen in **~60 percent of children** treated with cisplatin and can be as high as **90 percent**.^{5,8}

HOW IS IT TREATED?



Previously, intervention only occurred after hearing loss had been detected, and does not return normal hearing.

The most common management strategy is the **use of lifelong hearing aids**, which do not completely reverse hearing loss and require replacements every 3-5 years and may also require amplification technology.^{4,7}

Some children receive **difficult to manage cochlear (inner ear) implants**, which remain suboptimal in the direct recovery of hearing function and may also require replacement during an individual's lifetime.⁸

Studies have shown that hearing loss has a profound impact on children's learning and development at all ages



Despite recommendations, many pediatric cancer patients are not consistently monitored for hearing loss. Only 45% of patients have been documented to require hearing aids.¹²



Parents report children with hearing loss being held back a grade, problems with reading, math, attention and need for special education twice as often.¹²



Nearly 1 in 5 (18%) considered at-risk for hearing loss do not have hearing tests during follow-up.¹³



More than half (57%) of patients do not have full audiological monitoring before, during, and after treatment.¹³



Hearing loss is associated with lower IQ, phonetic decoding, and reading comprehension.¹²



Those with serious hearing loss are at an increased risk of not marrying, not graduating from high school, not living independently and unemployment.¹²

The cost of cisplatin-induced ototoxicity

Most insurance plans don't cover hearing aids and a pair of hearing aids can cost around \$6,000.⁹

A recent study within the Canadian health system estimated the total present value **lifetime costs** in the range of **\$445,000 to \$560,000** for patients with **severe hearing loss**, measured until the age of 64.¹⁰

In addition to the financial costs, ototoxicity takes a significant psychosocial and developmental toll on pediatric patients.¹¹

REFERENCES

- American Cancer Society. Key Statistics for Childhood Cancers. Last Revised: January 12, 2022. <https://www.cancer.org/cancer/cancer-in-children/key-statistics.html>
- Cone B, Dorn P, Konrad-Martin D, Lister J, Ortiz C, Schairer K. Ototoxic Medications (Medication Effects). American Speech-Language-Hearing Association. Retrieved from <https://www.asha.org/public/hearing/Ototoxic-Medications/>
- Rybak L. Mechanisms of Cisplatin Ototoxicity and Progress in Otoprotection. Current Opinion in Otolaryngology & Head and Neck Surgery. 2007; Vol. 15: 364 - 369
- Paken J, Govender C, Pillay M, et al. Cisplatin-Associated Ototoxicity: A Review for The Health Professional. Journal of Toxicology. Vol. 2016:1-13.
- Langer T, Zehnoff-Dinnesen A, Radtke S, et al. Understanding Platinum-Induced Ototoxicity. Trends in Pharmacological Sciences. August 2013, Vol. 34, No. 8: 458-469.

- Perkins SM, Shinohara ET, DeWees T, Frangoul H. Outcome for children with metastatic solid tumors over the last four decades. PLoS One. 2014;9(7):e100396. Surg. 2000;122(6):828-833.
- McCormick, B. (2014, February 07). 5 Common Questions About Hearing Aids: Starkey Blog. Retrieved from <https://www.starkey.com/blog/articles/2014/02/5-common-questions-about-hearing-aids>.
- Landier W. Ototoxicity and Cancer Therapy. Cancer. June 2016 Vol. 122, No. 11: 1647-1658.
- Blustein J, Weinstein BE. Opening the Market for Lower Cost Hearing Aids: Regulatory Change Can Improve the Health of Older Americans. Am J Public Health. 2016 Jun;106(6):1032-5. doi: 10.2105/AJPH.2016.303176. Epub 2016 Apr 14. PMID: 27077339; PMCID: PMC4880273.
- Dionne F, Mitton C, Rassekh R, et al. Economic Impact of A Genetic Test For Cisplatin-Induced Ototoxicity. The Pharmacogenomics Journal. 2012. Vol. 12, 201-213.

- Bass JK, Knight KR, Yock TI, et al. Evaluation and Management of Hearing Loss in Survivors of Childhood and Adolescent Cancers: A Report from the Children's Oncology Group. Pediatric Blood & Cancer. 2016 Jul;63(7):1152-1162.
- Hennegan, K, Silber A, Dehipawala S, Chithran K, Lockhart D. Evaluating the Burden of Survival of Platinum-induced Hearing Loss in Pediatric Solid Tumor Patients: A Systematic Literature Review. Poster PIH67. ISPOR Annual Meeting 2020
- Clemens 2019/pe29/col2/para2/lines1-6.